Number |
Keywords |
Number |
Keywords |
001
|
access to treatment |
071
|
media |
002
|
accessory gene |
072
|
men |
003
|
accountability |
073
|
men who have sex with men (MSM) |
004
|
adherance |
074
|
mental disorder |
005
|
adverse effect |
075
|
methodology |
006
|
advocacy |
076
|
microbicide |
007
|
affordable regimen |
077
|
migrant population |
008
|
alternative therapy |
078
|
mobile population |
009
|
animal model |
079
|
molecular epidemiology |
010
|
anti-retroviral drug/therapy |
080
|
monitoring |
011
|
armed force/police |
081
|
mother-to-child transmission |
012
|
awareness |
082
|
multilateral organization (UN, WTO etc) |
013
|
barrier |
083
|
network |
014
|
behavior |
084
|
non-governmental organization (NGO) |
015
|
blood safety |
085
|
nutrition |
016
|
business sector |
086
|
opportunistic infection |
017
|
capacity building |
087
|
orphan |
018
|
care/support |
088
|
outreach |
019
|
CD4 |
089
|
palliative care |
020
|
children |
090
|
participation |
021
|
clinical trial |
091
|
partnership |
022
|
community |
092
|
pathogenesis |
023
|
condom |
093
|
peer |
024
|
conflict/war |
094
|
people living with HIV/AIDS (PLWHA) |
025 |
counseling |
095 |
pharmacokinetics |
026 |
cross border |
096 |
polymorphism |
027 |
culture |
097 |
policy |
028 |
cytokine |
098 |
poverty |
029 |
development |
099 |
prevention |
030 |
diagnosis |
100 |
prison |
031 |
discrimination |
101 |
projection/estimation |
032 |
drug resistance |
102 |
qualitative study |
033 |
drug user |
103 |
quality of life (QOL) |
034 |
education |
104 |
rapid assessment |
035 |
empowerment |
105 |
refugee |
036 |
epidemiology |
106 |
religion |
037 |
ethical issue |
107 |
reproductive health |
038 |
ethnic group |
108 |
resource mobilization/allocation |
039 |
evaluation |
109 |
safer sex |
040 |
family |
110 |
salvage therapy |
041 |
female controlled prevention |
111 |
school |
042 |
fund raising/ funding |
112 |
self-help |
043 |
gay |
113 |
sex education |
044 |
gender |
114 |
sex worker |
045 |
generic drug |
115 |
sexual behavior |
046 |
greater involvement of PLWHA (GIPA) |
116 |
sexual minority |
047 |
Global Fund |
117 |
sexuality |
048 |
governance |
118 |
side effect |
049 |
governmental organization |
119 |
social marketing |
050 |
HAART |
120 |
socio-economic impact |
051 |
harm reduction |
121 |
STD/STI |
052 |
HCV co-infection |
122 |
stigma |
053 |
health care system |
123 |
surveillance |
054 |
HIV replication |
124 |
terminal care |
055 |
HIV specific immunity |
125 |
3 by 5 |
056 |
HIV subtype |
126 |
trafficking |
057 |
HIV testing |
127 |
training |
058 |
host factor |
128 |
transgender |
059 |
human rights |
129 |
treatment |
060 |
immune control |
130 |
tuberculosis |
061 |
immune reconstitution syndrome |
131 |
United Nations General Assembly Special Session |
062 |
income generation |
132 |
vaccine |
063 |
indigenous population |
133 |
violence |
064 |
injection |
134 |
viral load |
065 |
internet |
135 |
voluntary counseling and testing |
066 |
intervention |
136 |
vulnerability |
067 |
involvement |
137 |
welfare |
068 |
latent infection |
138 |
women |
069 |
leadership |
139 |
workplace |
070 |
legal issue |
140 |
youth |